Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.

ABSTRACT: Endocrine therapies targeting oestrogen signalling have significantly improved breast cancer management. However, their efficacy is limited by intrinsic and acquired resistance to treatment, which remains a major challenge for oestrogen receptor α (ERα)-positive tumours. Though many studies using in vitro models of endocrine resistance have identified putative actors of resistance, no consensus has been reached. We demonstrated previously that oestrogen non-genomic signalling, characterized by the formation of the ERα/Src/PI3K complex, is activated in aggressive breast cancers (BC). We wondered herein whether the activation of this pathway is also involved in resistance to endocrine therapies. We studied the interactions between ERα and Src or PI3K by proximity ligation assay (PLA) in in-v

SUBMITTER: Poulard C 

PROVIDER: S-EPMC6600329 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature